

World Journal of *Clinical Cases*

World J Clin Cases 2022 July 16; 10(20): 6759-7186



OPINION REVIEW

- 6759 Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum?

Cigrovski Berkovic M, Rezig T, Bilic-Curcic I, Mrzljak A

MINIREVIEWS

- 6769 Drainage of pancreatic fluid collections in acute pancreatitis: A comprehensive overview

Bansal A, Gupta P, Singh AK, Shah J, Samanta J, Mandavdhare HS, Sharma V, Sinha SK, Dutta U, Sandhu MS, Kochhar R

- 6784 Frontiers of COVID-19-related myocarditis as assessed by cardiovascular magnetic resonance

Luo Y, Liu BT, Yuan WF, Zhao CX

ORIGINAL ARTICLE

Case Control Study

- 6794 Urinary and sexual function changes in benign prostatic hyperplasia patients before and after transurethral columnar balloon dilatation of the prostate

Zhang DP, Pan ZB, Zhang HT

- 6803 Effects of the information-knowledge-attitude-practice nursing model combined with predictability intervention on patients with cerebrovascular disease

Huo HL, Gui YY, Xu CM, Zhang Y, Li Q

Retrospective Cohort Study

- 6811 Effects of Kampo medicine hangebyakujutsutemmato on persistent postural-perceptual dizziness: A retrospective pilot study

Miwa T, Kanemaru SI

Retrospective Study

- 6825 Longitudinal changes in personalized platelet count metrics are good indicators of initial 3-year outcome in colorectal cancer

Herold Z, Herold M, Lohinszky J, Szasz AM, Dank M, Somogyi A

- 6845 Efficacy of Kegel exercises in preventing incontinence after partial division of internal anal sphincter during anal fistula surgery

Garg P, Yagnik VD, Kaur B, Menon GR, Dawka S

Observational Study

- 6855 Influence of the water jet system vs cavitron ultrasonic surgical aspirator for liver resection on the remnant liver

Hanaki T, Tsuda A, Sunaguchi T, Goto K, Morimoto M, Murakami Y, Kihara K, Matsunaga T, Yamamoto M, Tokuyasu N, Sakamoto T, Hasegawa T, Fujiwara Y

- 6865** Critical values of monitoring indexes for perioperative major adverse cardiac events in elderly patients with biliary diseases

Zhang ZM, Xie XY, Zhao Y, Zhang C, Liu Z, Liu LM, Zhu MW, Wan BJ, Deng H, Tian K, Guo ZT, Zhao XZ

- 6876** Comparative study of surface electromyography of masticatory muscles in patients with different types of bruxism

Lan KW, Jiang LL, Yan Y

Randomized Controlled Trial

- 6890** Dural puncture epidural technique provides better anesthesia quality in repeat cesarean delivery than epidural technique: Randomized controlled study

Wang SY, He Y, Zhu HJ, Han B

SYSTEMATIC REVIEWS

- 6900** Network pharmacology-based strategy for predicting therapy targets of Sanqi and Huangjing in diabetes mellitus

Cui XY, Wu X, Lu D, Wang D

META-ANALYSIS

- 6915** Endoscopic submucosal dissection for early signet ring cell gastric cancer: A systematic review and meta-analysis

Weng CY, Sun SP, Cai C, Xu JL, Lv B

- 6927** Prognostic value of computed tomography derived skeletal muscle mass index in lung cancer: A meta-analysis

Pan XL, Li HJ, Li Z, Li ZL

CASE REPORT

- 6936** Autosomal dominant osteopetrosis type II resulting from a *de novo* mutation in the *CLCN7* gene: A case report

Song XL, Peng LY, Wang DW, Wang H

- 6944** Clinical expression and mitochondrial deoxyribonucleic acid study in twins with 14484 Leber's hereditary optic neuropathy: A case report

Chuenkongkaew WL, Chinkulkitnivat B, Lertrit P, Chirapapaisan N, Kaewsutthi S, Suktitipat B, Mitrpant C

- 6954** Management of the enteroatmospheric fistula: A case report

Cho J, Sung K, Lee D

- 6960** Lower lip recurrent keratoacanthoma: A case report

Liu XG, Liu XG, Wang CJ, Wang HX, Wang XX

- 6966** Optic disc coloboma associated with macular retinoschisis: A case report

Zhang W, Peng XY

- 6974** A 7-year-old boy with recurrent cyanosis and tachypnea: A case report
Li S, Chen LN, Zhong L
- 6981** Schwannomatosis patient who was followed up for fifteen years: A case report
Li K, Liu SJ, Wang HB, Yin CY, Huang YS, Guo WT
- 6991** Intentional replantation combined root resection therapy for the treatment of type III radicular groove with two roots: A case report
Tan D, Li ST, Feng H, Wang ZC, Wen C, Nie MH
- 6999** Clinical features and genetic variations of severe neonatal hyperbilirubinemia: Five case reports
Lin F, Xu JX, Wu YH, Ma YB, Yang LY
- 7006** Percutaneous transhepatic access for catheter ablation of a patient with heterotaxy syndrome complicated with atrial fibrillation: A case report
Wang HX, Li N, An J, Han XB
- 7013** Secondary positioning of rotationally asymmetric refractive multifocal intraocular lens in a patient with glaucoma: A case report
Fan C, Zhou Y, Jiang J
- 7020** Laparoscopic repair of diaphragmatic hernia associating with radiofrequency ablation for hepatocellular carcinoma: A case report
Tsunoda J, Nishi T, Ito T, Inaguma G, Matsuzaki T, Seki H, Yasui N, Sakata M, Shimada A, Matsumoto H
- 7029** Hypopituitary syndrome with pituitary crisis in a patient with traumatic shock: A case report
Zhang XC, Sun Y
- 7037** Solitary plasmacytoma of the left rib misdiagnosed as angina pectoris: A case report
Yao J, He X, Wang CY, Hao L, Tan LL, Shen CJ, Hou MX
- 7045** Secondary coronary artery ostial lesions: Three case reports
Liu XP, Wang HJ, Gao JL, Ma GL, Xu XY, Ji LN, He RX, Qi BYE, Wang LC, Li CQ, Zhang YJ, Feng YB
- 7054** Bladder perforation injury after percutaneous peritoneal dialysis catheterization: A case report
Shi CX, Li ZX, Sun HT, Sun WQ, Ji Y, Jia SJ
- 7060** Myotonic dystrophy type 1 presenting with dyspnea: A case report
Jia YX, Dong CL, Xue JW, Duan XQ, Xu MY, Su XM, Li P
- 7068** Novel mutation in the *SALL1* gene in a four-generation Chinese family with uraemia: A case report
Fang JX, Zhang JS, Wang MM, Liu L
- 7076** Malignant transformation of primary mature teratoma of colon: A case report
Liu J

- 7082** Treatment of pyogenic liver abscess by surgical incision and drainage combined with platelet-rich plasma: A case report
Wang JH, Gao ZH, Qian HL, Li JS, Ji HM, Da MX
- 7090** Left bundle branch pacing in a ventricular pacing dependent patient with heart failure: A case report
Song BX, Wang XX, An Y, Zhang YY
- 7097** Solitary fibrous tumor of the liver: A case report and review of the literature
Xie GY, Zhu HB, Jin Y, Li BZ, Yu YQ, Li JT
- 7105** MutL homolog 1 germline mutation c.(453+1_454-1)_(545+1_546-1)del identified in lynch syndrome: A case report and review of literature
Zhang XW, Jia ZH, Zhao LP, Wu YS, Cui MH, Jia Y, Xu TM
- 7116** Malignant histiocytosis associated with mediastinal germ cell tumor: A case report
Yang PY, Ma XL, Zhao W, Fu LB, Zhang R, Zeng Q, Qin H, Yu T, Su Y
- 7124** Immunoglobulin G4 associated autoimmune cholangitis and pancreatitis following the administration of nivolumab: A case report
Agrawal R, Guzman G, Karimi S, Giulianotti PC, Lora AJM, Jain S, Khan M, Boulay BR, Chen Y
- 7130** Portal vein thrombosis in a noncirrhotic patient after hemihepatectomy: A case report and review of literature
Zhang SB, Hu ZX, Xing ZQ, Li A, Zhou XB, Liu JH
- 7138** Microvascular decompression for a patient with oculomotor palsy caused by posterior cerebral artery compression: A case report and literature review
Zhang J, Wei ZJ, Wang H, Yu YB, Sun HT
- 7147** Topical halometasone cream combined with fire needle pre-treatment for treatment of primary cutaneous amyloidosis: Two case reports
Su YQ, Liu ZY, Wei G, Zhang CM
- 7153** Simultaneous robot-assisted approach in a super-elderly patient with urothelial carcinoma and synchronous contralateral renal cell carcinoma: A case report
Yun JK, Kim SH, Kim WB, Kim HK, Lee SW
- 7163** Nursing a patient with latent autoimmune diabetes in adults with insulin-related lipodystrophy, allergy, and exogenous insulin autoimmune syndrome: A case report
He F, Xu LL, Li YX, Dong YX
- 7171** Incidental diagnosis of medullary thyroid carcinoma due to persistently elevated procalcitonin in a patient with COVID-19 pneumonia: A case report
Saha A, Mukhopadhyay M, Paul S, Bera A, Bandyopadhyay T
- 7178** Macular hole following phakic intraocular lens implantation: A case report
Li XJ, Duan JL, Ma JX, Shang QL

LETTER TO THE EDITOR

- 7184** Is every microorganism detected in the intensive care unit a nosocomial infection? Isn't prevention more important than detection?

Yildirim F, Karaman I, Yildirim M

ABOUT COVER

Editorial Board Member of *World Journal of Clinical Cases*, Jie-Feng Huang, PhD, Associate Chief Physician, Associate Professor, Department of Orthopaedics and Traumatology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310006, Zhejiang Province, China. 40983285@qq.com

AIMS AND SCOPE

The primary aim of *World Journal of Clinical Cases* (WJCC, *World J Clin Cases*) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

INDEXING/ABSTRACTING

The WJCC is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Current Contents®/Clinical Medicine, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 Edition of Journal Citation Reports® cites the 2021 impact factor (IF) for WJCC as 1.534; IF without journal self cites: 1.491; 5-year IF: 1.599; Journal Citation Indicator: 0.28; Ranking: 135 among 172 journals in medicine, general and internal; and Quartile category: Q4. The WJCC's CiteScore for 2021 is 1.2 and Scopus CiteScore rank 2021: General Medicine is 443/826.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: *Hua-Ge Yin*; Production Department Director: *Xu Guo*; Editorial Office Director: *Jin-Lei Wang*.

NAME OF JOURNAL

World Journal of Clinical Cases

ISSN

ISSN 2307-8960 (online)

LAUNCH DATE

April 16, 2013

FREQUENCY

Thrice Monthly

EDITORS-IN-CHIEF

Bao-Gan Peng, Jerzy Tadeusz Chudek, George Kontogeorgos, Maurizio Serati, Ja Hyeon Ku

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/2307-8960/editorialboard.htm>

PUBLICATION DATE

July 16, 2022

COPYRIGHT

© 2022 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>



Prognostic value of computed tomography derived skeletal muscle mass index in lung cancer: A meta-analysis

Xue-Lin Pan, Hong-Jun Li, Zhen Li, Zhen-Lin Li

Specialty type: Medicine, research and experimental

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0
Grade B (Very good): 0
Grade C (Good): C, C
Grade D (Fair): 0
Grade E (Poor): 0

P-Reviewer: Geng J, China;
Ozdemir HI, Turkey

A-Editor: Liu X, China

Received: December 5, 2021

Peer-review started: December 5, 2021

First decision: January 25, 2022

Revised: January 26, 2022

Accepted: May 22, 2022

Article in press: May 22, 2022

Published online: July 16, 2022



Xue-Lin Pan, Zhen Li, Zhen-Lin Li, Department of Radiology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China

Hong-Jun Li, West China Hospital of Medicine, Sichuan University, Chengdu 610041, Sichuan Province, China

Corresponding author: Zhen-Lin Li, MD, Professor, Department of Radiology, West China Hospital, Sichuan University, No. 37 Guoxuexiang, Chengdu 610041, Sichuan Province, China. 17380096151@163.com

Abstract

BACKGROUND

The prognostic role of the skeletal muscle mass index (SMI) derived from computed tomography (CT) imaging been well verified in several types of cancers. However, whether the SMI could serve as a reliable and valuable predictor of long-term survival in lung cancer patients remains unclear.

AIM

To identify the prognostic value of the CT-derived SMI in lung cancer patients.

METHODS

The PubMed, Web of Science, and Embase electronic databases were searched up to November 5, 2021 for relevant studies. The Reference Citation Analysis databases were used during the literature searching and selection. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated to assess the association of the SMI with the overall survival (OS) of lung cancer patients. All statistical analyses were performed with STATA 12.0 software.

RESULTS

A total of 12 studies involving 3002 patients were included. The pooled results demonstrated that a lower SMI was significantly related to poorer OS (HR = 1.23, 95%CI: 1.11-1.37, $P < 0.001$). In addition, the subgroup analyses stratified by treatment (nonsurgery *vs* surgery), tumor stage (advanced stage *vs* early stage), and tumor type (non-small cell lung cancer *vs* lung cancer) showed similar results.

CONCLUSION

The CT-derived SMI is a novel and valuable prognostic indicator in lung cancer and might contribute to the clinical management and treatment of lung cancer patients.

Key Words: Skeletal muscle mass index; Computed tomography; Lung cancer; Prognosis; Meta-analysis

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: We searched the PubMed, Web of Science, and Embase electronic databases up to November 5, 2021, and a total of 12 studies involving 3002 patients were included. The pooled results demonstrated that a lower skeletal muscle mass index (SMI) was significantly related to poorer overall survival ($P < 0.001$). In addition, the subgroup analyses stratified by treatment (nonsurgery vs surgery), tumor stage (advanced stage vs early stage), and tumor type (non-small cell lung cancer vs lung cancer) showed similar results. The computed tomography-derived SMI is a novel and valuable prognostic indicator in lung cancer and might contribute to the clinical management and treatment of lung cancer patients.

Citation: Pan XL, Li HJ, Li Z, Li ZL. Prognostic value of computed tomography derived skeletal muscle mass index in lung cancer: A meta-analysis. *World J Clin Cases* 2022; 10(20): 6927-6935

URL: <https://www.wjgnet.com/2307-8960/full/v10/i20/6927.htm>

DOI: <https://dx.doi.org/10.12998/wjcc.v10.i20.6927>

INTRODUCTION

Lung cancer is the leading cause of tumor-related deaths worldwide and can be categorized into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC)[1,2]. Despite considerable advances in the clinical diagnosis, treatment, and management of lung cancer, the overall prognosis of lung cancer patients remains poor[3,4]. The tumor-node-metastasis (TNM) staging system is still the most authoritative tool to assess the disease severity and prognosis of lung cancer patients. However, in addition to disease stage, the prognosis of lung cancer patients can be affected or predicted by many factors.

In recent years, an increasing number of common clinical indicators have been identified to play a role in the evaluation of long-term survival in lung cancer, such as the D-dimer level, albumin-to-globulin ratio (AGR), lymphocyte-to-monocyte ratio, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio[5-8]. However, these blood indicators are unstable and may be changed by a number of factors or diseases. There are also some other stable prognostic indicators, such as ctDNA and circulating tumor cells[9-11], but they are relatively expensive and cannot be widely applied in clinics.

The skeletal muscle mass index (SMI) is calculated according to computed tomography (CT) images and can reflect the nutritional status of the body to a large extent. In addition, the two indicators, the area of skeletal muscle and height, involved in the calculation of SMI are both stable and reliable. The prognostic value of SMI in several cancers has been identified, such as gastric cancer, colorectal cancer, pancreatic adenocarcinoma, and renal cell carcinoma[12-16]. However, whether SMI could serve as a reliable and valuable prognostic index in lung cancer remains unclear.

Thus, the aim of this meta-analysis was to assess the prognostic role of CT-derived SMI in lung cancer, which might contribute to the evaluation of long-term survival and the formulation of therapy strategies for lung cancer patients.

MATERIALS AND METHODS

This meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA 2020) checklist and has been registered in PROSPERO.

Literature retrieval

The PubMed, Web of Science, and Embase electronic databases were searched from inception to November 5, 2021. The search strategy consisted of Medical Subject Heading terms and free-text terms with logical operators. The following terms were used during the literature search: Skeletal muscle mass index, SMI, lung, pulmonary, tumor, cancer, carcinoma, neoplasm, prognostic, survival, and prognosis. In detail, the specific search strategy was as follows: (Skeletal muscle mass index OR SMI) AND (lung OR pulmonary) AND (tumor OR cancer OR carcinoma OR neoplasm) AND (prognostic OR survival OR prognosis). In addition, the reference lists of the included studies were searched to identify additional eligible studies.

Inclusion and exclusion criteria

The inclusion criteria were as follows: (1) Patients were pathologically diagnosed with lung cancer; (2) The SMI was calculated through CT images before antitumor treatment; and (3) The association between the SMI and overall survival (OS) was explored and assessed by hazard ratios (HRs) with 95% confidence intervals (CIs).

The exclusion criteria were as follows: (1) The HRs with 95% CIs were not directly reported in articles; (2) Reviews, meeting abstracts, letters, editorials, or case reports; and (3) Overlapping or duplicated data.

The Reference Citation Analysis databases were used during the literature searching and selection.

Data extraction

The following information was collected from the included studies: The first author, publication year, country, sample size, treatment (nonsurgery *vs* surgery), TNM stage, cutoff value of the SMI, tumor type, and HR with corresponding 95% CI.

Study quality assessment

The quality of the included studies was evaluated according to the Newcastle Ottawa Scale (NOS), and studies with an NOS score of 6 or higher were defined as high-quality studies[17].

The literature retrieval, selection, data extraction, and quality assessment were all conducted by two investigators independently. Any disagreement was resolved by team discussion.

Statistical analysis

All statistical analyses were conducted with STATA 12.0 software (College Station, TX, United States). The HRs with 95% CIs were calculated to assess the association between the SMI and OS. Heterogeneity was evaluated by Cochran's Q test and Higgins I^2 statistic; $P < 0.10$ and/or $I^2 > 50\%$ were defined as significant heterogeneity among studies, and the random effects model was applied for the pooled effect estimates; otherwise, the fixed effects model was used[18]. Subgroup analyses stratified by the treatment, tumor stage, and tumor type were further conducted. Sensitivity analysis for OS was performed by removing individual studies from the meta-analysis each time. Begg's funnel plot and Egger's test were conducted to evaluate publication bias. Significant publication bias was defined as a P -value less than 0.05, and the trim-and-fill method was applied to assess the influence of potentially unpublished papers on the stability of the pooled results[19].

RESULTS

Literature retrieval and selection

The detailed literature retrieval and selection process is presented in Figure 1. Ultimately, a total of 12 relevant retrospective studies were included in this meta-analysis[20-31].

Basic characteristics of the included studies

A total of 3002 lung cancer patients were enrolled among the 12 studies, with sample sizes ranging from 46 to 734. In most included studies, the patients were diagnosed at an advanced stage and received nonsurgical treatment. In addition, most studies only included NSCLC patients, and all studies were of high quality, with an NOS score of 6 or higher (Table 1).

Results of meta-analysis for association between SMI and OS

The pooled results demonstrated that a lower SMI was significantly related to poorer OS in lung cancer patients (HR = 1.23, 95% CI: 1.11-1.37, $P < 0.001$; $I^2 = 84.7\%$, $P < 0.001$) (Figure 2). Then, subgroup analyses based on the treatment [nonsurgery (HR = 1.15, 95% CI: 1.06-1.26, $P = 0.002$) *vs* surgery (HR = 5.71, 95% CI: 2.94-11.10, $P < 0.001$)], tumor stage [advanced stage (HR = 1.34, 95% CI: 1.07-1.68, $P = 0.011$) *vs* early stage (HR = 5.71, 95% CI: 2.94-11.10, $P < 0.001$)], and tumor type [NSCLC (HR = 1.97, 95% CI: 1.33-2.93, $P = 0.001$) *vs* lung cancer (HR = 1.07, 95% CI: 1.03-1.11, $P < 0.001$)] were performed, which showed similar results (Table 2). In addition, according to the subgroup analysis, the treatment strategy and tumor stage might be potential sources of heterogeneity (Table 2).

Sensitivity analysis

The sensitivity analysis indicated that the results of this meta-analysis were stable and that none of the included studies had a significant impact on the overall results (Figure 3).

Publication bias

Begg's funnel plot was asymmetric (Figure 4A), and Egger's test was significant ($P < 0.001$); therefore, significant publication bias was observed. The trim-and-fill method was used to detect potentially

Table 1 Basic characteristics of included studies

Ref.	Year	Country	Sample size	Treatment	TNM stage	Threshold of SMI (cm ² /m ²)	Tumor type	NOS
Jafri <i>et al</i> [20]	2015	United States	112	Non-surgery	IV	40	NSCLC	7
Suzuki <i>et al</i> [22]	2016	Japan	90	Surgery	I	Male: 43.75; female: 41.10	NSCLC	7
Sjøblom <i>et al</i> [21]	2016	Norway	734	Non-surgery	III-IV	NR	NSCLC	7
Shoji <i>et al</i> [24]	2017	Japan	147	Surgery	I	Male: 43.75; female: 41.10	NSCLC	7
Nattenmüller <i>et al</i> [23]	2017	Germany	200	Non-surgery	I-IV	NR	LC	7
Roch <i>et al</i> [28]	2020	France	142	Non-surgery	NR	Male: 52.4; female: 38.5	NSCLC	6
Abbass <i>et al</i> [25]	2020	United Kingdom	643	Non-surgery	III-IV	Male: 43; female: 41	LC	6
Dolan <i>et al</i> [26]	2020	United Kingdom	119	Non-surgery	I-III	Male: 53; female: 41	NSCLC	6
Magri <i>et al</i> [27]	2019	Israel	46	Non-surgery	IV	NR	LC	6
Katsui <i>et al</i> [29]	2021	Japan	60	Non-surgery	III	Male: 43; female: 24	NSCLC	7
Lee <i>et al</i> [30]	2021	Republic of Korea	70	Non-surgery	IIIB-IV	Male: 46; female: 29	SCC	6
Yang <i>et al</i> [31]	2021	China	639	Non-surgery	IIIB-IV	Male: 32.48; female: 27.82	NSCLC	7

TNM: Tumor-node-metastasis; SMI: Skeletal muscle mass index; NOS: Newcastle-Ottawa Scale; NR: Not reported; NSCLC: Non-small cell lung cancer; LC: Lung cancer; SCC: Squamous cell cancer.

Table 2 Results of meta-analysis

	No. of studies	HR	95%CI	P value	P (%)	P value
Overall survival	12	1.23	1.11-1.37	< 0.001	84.7	< 0.001
Treatment						
Non-surgery	10	1.15	1.06-1.26	0.002	80.4	< 0.001
Surgery	2	5.71	2.94-11.10	< 0.001	0.0	0.655
Tumor stage						
Advanced stage	7	1.34	1.07-1.68	0.011	80.8	< 0.001
Early stage	2	5.71	2.94-11.10	< 0.001	0.0	0.655
Tumor type						
Non-small cell lung cancer	9	1.97	1.33-2.93	0.001	87.3	< 0.001
Lung cancer	3	1.07	1.03-1.11	< 0.001	0.0	0.471

HR: Hazard ratios; CI: Confidence interval.

unpublished articles and their impact on the overall results. Six potentially unpublished papers were identified (Figure 4B), and the pooled HR was 1.019 (95%CI: 1.005-1.033, $P = 0.006$) and 1.063 (95%CI: 0.949-1.192, $P = 0.293$) after combining these six studies, respectively. Thus, the six potentially unpublished studies might impact the overall results, and more high-quality studies are still needed to verify the above findings.

DISCUSSION

The current meta-analysis demonstrated that a lower pretreatment CT-derived SMI was significantly associated with poorer OS in lung cancer patients and might serve as a reliable and valuable prognostic indicator in lung cancer. The results of subgroup analyses based on the treatment, tumor stage, and tumor type all further verified the above findings.




Figure 1 Flow diagram of the meta-analysis.




Figure 2 Forest plot for association between skeletal muscle mass index and overall survival of lung cancer patients.

The SMI is a novel indicator reflecting nutritional status, and it is well known that the nutritional condition of the body is essential for the prognosis of lung cancer patients. The clinical role of a number of nutritional indicators has been widely explored in lung cancer. Li *et al*[6] included eight studies involving 3496 patients and demonstrated that a low pretreatment AGR was a predictor of poor OS (HR = 1.88, 95%CI: 1.49-2.38, $P < 0.001$) and disease-free survival (DFS) (HR = 2.09, 95%CI: 1.56-2.81, $P < 0.001$) in lung cancer[6]. In addition, Li *et al*[32] included ten relevant studies involving 5085 patients and showed that a low prognostic nutritional index calculated based on the peripheral serum albumin level and total lymphocyte count was significantly related to unfavorable OS (HR = 1.72, 95%CI: 1.43-2.06, $P = 0.000$) in lung cancer, especially in NSCLC (HR = 1.93, 95%CI: 1.56-2.37, $P = 0.000$)[32]. Furthermore, a high pretreatment controlling nutritional status score calculated based on the peripheral serum albumin level, total blood cholesterol level, and total lymphocyte count was identified to be positively correlated with poor OS (HR = 1.63, 95%CI: 1.40-1.88, $P < 0.001$), DFS/recurrence-free survival (HR = 1.65, 95%CI: 1.35-2.01, $P < 0.001$), and postoperative complications (odds ratio = 1.58, 95%CI: 1.21-2.06, $P = 0.001$) in NSCLC patients[33]. However, the clinical application of these indices is severely limited because they are unstable and could be affected by many factors.




Figure 3 Sensitivity analysis of association between skeletal muscle mass index and overall survival of lung cancer patients.




Figure 4 Association between skeletal muscle mass index and overall survival of lung cancer patients. A: Begg's funnel plot; B: Filled funnel plot.

In most of the included studies, the patients were divided into high or low SMI groups according to the values of SMI. However, the thresholds of SMI in the included studies were different, which means that the optimal cutoff values of SMI in different groups of lung cancer should be inconsistent. Although most relevant studies differentiated cutoff values based on sex, we deem that age should also be considered because age is a very important factor affecting the basic nutritional status. Thus, more rigorously differentiated thresholds should be applied in future relevant studies. In addition, SCLC is a pathological type with a high degree of malignancy and rapid progression, and most SCLC patients are diagnosed at an advanced stage. SCLC patients are prone to recurrence and metastasis, and the application of the current staging system for SCLC is extremely limited clinically. Unfortunately, none of the included studies focused on this type of lung cancer and explored the prognostic value of the SMI in SCLC. However, we believe that the SMI might be a novel and valuable predictor of survival and therapeutic effects in SCLC patients. Thus, we hope that more scholars could pay attention to the clinical role of the SMI in SCLC in the future.

There are several limitations in this meta-analysis. First, all included studies were retrospective, and the sample sizes were relatively small. Second, more specific subgroup analyses could not be conducted due to the lack of detailed data. Third, significant heterogeneity was observed in our meta-analysis, but the sources of heterogeneity were not identified.

CONCLUSION

The CT-derived SMI is a novel and valuable prognostic indicator in lung cancer and might contribute to the clinical management and treatment of lung cancer patients. However, more prospective high-quality studies are still needed to verify the above findings.

ARTICLE HIGHLIGHTS

Research background

The prognostic role of the skeletal muscle mass index (SMI) calculated through computed tomography (CT) images in several types of cancers has been demonstrated.

Research motivation

Whether the SMI could serve as a reliable and valuable predictor for long-term survival in lung cancer remains unclear.

Research objectives

To verify the prognostic value of the CT-derived SMI in lung cancer patients.

Research methods

Several electronic databases were searched up to November 5, 2021 for relevant studies. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated to assess the association of the SMI with the overall survival (OS) of lung cancer patients. All statistical analyses were performed with STATA 12.0 software.

Research results

The pooled results demonstrated that a lower SMI was significantly related to poorer OS (HR = 1.23, 95%CI: 1.11-1.37, $P < 0.001$). In addition, the subgroup analyses stratified by treatment (nonsurgery *vs* surgery), tumor stage (advanced stage *vs* early stage), and tumor type (non-small cell lung cancer *vs* lung cancer) showed similar results.

Research conclusions

The CT-derived SMI is a novel and valuable prognostic indicator in lung cancer.

Research perspectives

The SMI might contribute to the clinical management and treatment of lung cancer patients.

FOOTNOTES

Author contributions: Li ZL made substantial contributions to the conception and design of the work; Pan XL and Li HJ searched and selected the materials and extracted the data; Pan XL wrote the manuscript; Pan XL, Li HJ, Li Z, and Li ZL revised the paper carefully and also contributed to the statistical analysis; all authors have read and approved the final manuscript.

Supported by 135 Project for Disciplines of Excellence, West China Hospital, Sichuan University, No. ZYGD18019.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: China

ORCID number: Xue-Lin Pan 0000-0003-1077-0829; Hong-Jun Li 0000-0002-6012-1598; Zhen Li 0000-0001-8177-1189; Zhen-Lin Li 0000-0002-9332-1887.

S-Editor: Fan JR

L-Editor: Wang TQ

P-Editor: Fan JR

REFERENCES

- 1 Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. *Chin Med J (Engl)* 2021; **134**: 783-791 [PMID: [33734139](#) DOI: [10.1097/CM9.0000000000001474](#)]
- 2 Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. *Int J Cancer* 2021 [PMID: [33818764](#) DOI: [10.1002/ijc.33588](#)]
- 3 American Cancer Society *Cancer Statistics 2021* Report. *J Nucl Med* 2021; **62**: 12N [PMID: [33622967](#)]
- 4 Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. *CA Cancer J Clin* 2021; **71**: 7-33 [PMID: [33433946](#) DOI: [10.3322/caac.21654](#)]
- 5 Li J, Wang Y, Li J, Che G. Prognostic Value of Pretreatment D-Dimer Level in Small-Cell Lung Cancer: A Meta-Analysis. *Technol Cancer Res Treat* 2021; **20**: 1533033821989822 [PMID: [33563114](#) DOI: [10.1177/1533033821989822](#)]
- 6 Li J, Wang Y, Wu Y, Li J, Che G. Prognostic Value of Pretreatment Albumin to Globulin Ratio in Lung Cancer: A Meta-Analysis. *Nutr Cancer* 2021; **73**: 75-82 [PMID: [32148098](#) DOI: [10.1080/01635581.2020.1737155](#)]
- 7 Wang Y, Hu X, Xu W, Wang H, Huang Y, Che G. Prognostic value of a novel scoring system using inflammatory response biomarkers in non-small cell lung cancer: A retrospective study. *Thorac Cancer* 2019; **10**: 1402-1411 [PMID: [31104359](#) DOI: [10.1111/1759-7714.13085](#)]
- 8 Wang Y, Huang D, Xu WY, Wang YW, Che GW. Prognostic Value of Pretreatment Lymphocyte-to-Monocyte Ratio in Non-Small Cell Lung Cancer: A Meta-Analysis. *Oncol Res Treat* 2019; **42**: 523-531 [PMID: [31319409](#) DOI: [10.1159/000501726](#)]
- 9 Xia L, Mei J, Kang R, Deng S, Chen Y, Yang Y, Feng G, Deng Y, Gan F, Lin Y, Pu Q, Ma L, Lin F, Yuan Y, Hu Y, Guo C, Liao H, Liu C, Zhu Y, Wang W, Liu Z, Xu Y, Li K, Li C, Li Q, He J, Chen W, Zhang X, Kou Y, Wang Y, Wu Z, Che G, Chen L, Liu L. Perioperative ctDNA-Based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1). *Clin Cancer Res* 2021 [PMID: [34844976](#) DOI: [10.1158/1078-0432.CCR-21-3044](#)]
- 10 Li H, Li B, Pan Y, Zhang Y, Xiang J, Sun Y, Yu X, He W, Hu H. Preoperative Folate Receptor-Positive Circulating Tumor Cell Level Is a Prognostic Factor of Long Term Outcome in Non-Small Cell Lung Cancer Patients. *Front Oncol* 2020; **10**: 621435 [PMID: [33585249](#) DOI: [10.3389/fonc.2020.621435](#)]
- 11 Yang L, Yan X, Chen J, Zhan Q, Hua Y, Xu S, Li Z, Wang Z, Dong Y, Zuo D, Xue M, Tang Y, Herschman HR, Lu S, Shi Q, Wei W. Hexokinase 2 discerns a novel circulating tumor cell population associated with poor prognosis in lung cancer patients. *Proc Natl Acad Sci U S A* 2021; **118** [PMID: [33836566](#) DOI: [10.1073/pnas.2012281118](#)]
- 12 Kim EY, Jun KH, Kim SY, Chin HM. Body mass index and skeletal muscle index are useful prognostic factors for overall survival after gastrectomy for gastric cancer: Retrospective cohort study. *Medicine (Baltimore)* 2020; **99**: e23363 [PMID: [33217879](#) DOI: [10.1097/MD.00000000000023363](#)]
- 13 Kang Z, Cheng L, Li K, Shuai Y, Xue K, Zhong Y, Chen L. Correlation between L3 skeletal muscle index and prognosis of patients with stage IV gastric cancer. *J Gastrointest Oncol* 2021; **12**: 2073-2081 [PMID: [34790375](#) DOI: [10.21037/jgo-21-556](#)]
- 14 Lee J, Suh J, Song C, You D, Jeong IG, Hong B, Hong JH, Kim CS, Ahn H. Association Between Sarcopenia and Survival of Patients with Organ-Confined Renal Cell Carcinoma after Radical Nephrectomy. *Ann Surg Oncol* 2022; **29**: 2473-2479 [PMID: [34625877](#) DOI: [10.1245/s10434-021-10881-7](#)]
- 15 Malik M, Michalak M, Radecka B, Gelej M, Jackowska A, Filipczyk-Cisarz E, Hetman K, Foszczyńska-Kłoda M, Kania-Zembaczynska B, Mańka D, Orlikowska M, Rogowska-Droś H, Bodnar L. Prognostic Value of Sarcopenia in Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil. *J Clin Med* 2021; **10** [PMID: [34768626](#) DOI: [10.3390/jcm10215107](#)]
- 16 Rom H, Tamir S, Van Vugt JLA, Berger Y, Perl G, Morgenstern S, Tovar A, Brenner B, Benchimol D, Kashtan H, Sadot E. Sarcopenia as a Predictor of Survival in Patients with Pancreatic Adenocarcinoma After Pancreatectomy. *Ann Surg Oncol* 2022; **29**: 1553-1563 [PMID: [34716836](#) DOI: [10.1245/s10434-021-10995-y](#)]
- 17 Luchini C, Stubbs B, Solmi M, Veronese N. Assessing the quality of studies in meta-analyses: Advantages and limitations of the Newcastle Ottawa Scale. *World J Meta-Anal* 2017; **5**: 80-84 [DOI: [10.13105/wjma.v5.i4.80](#)]
- 18 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003; **327**: 557-560 [PMID: [12958120](#) DOI: [10.1136/bmj.327.7414.557](#)]
- 19 Wang Y, Li J, Chang S, Dong Y, Che G. Risk and Influencing Factors for Subsequent Primary Lung Cancer After Treatment of Breast Cancer: A Systematic Review and Two Meta-Analyses Based on Four Million Cases. *J Thorac Oncol* 2021; **16**: 1893-1908 [PMID: [34256110](#) DOI: [10.1016/j.jtho.2021.07.001](#)]
- 20 Jafri SH, Previgliano C, Khandelwal K, Shi R. Cachexia Index in Advanced Non-Small-Cell Lung Cancer Patients. *Clin Med Insights Oncol* 2015; **9**: 87-93 [PMID: [26604850](#) DOI: [10.4137/CMO.S30891](#)]
- 21 Sjøblom B, Grønberg BH, Wentzel-Larsen T, Baracos VE, Hjermstad MJ, Aass N, Bremnes RM, Fløtten Ø, Bye A, Jordhøy M. Skeletal muscle radiodensity is prognostic for survival in patients with advanced non-small cell lung cancer. *Clin Nutr* 2016; **35**: 1386-1393 [PMID: [27102408](#) DOI: [10.1016/j.clnu.2016.03.010](#)]
- 22 Suzuki Y, Okamoto T, Fujishita T, Katsura M, Akamine T, Takamori S, Morodomi Y, Tagawa T, Shoji F, Maehara Y. Clinical implications of sarcopenia in patients undergoing complete resection for early non-small cell lung cancer. *Lung Cancer* 2016; **101**: 92-97 [PMID: [27794415](#) DOI: [10.1016/j.lungcan.2016.08.007](#)]

- 23 **Nattenmüller J**, Wochner R, Muley T, Steins M, Hummler S, Teucher B, Wiskemann J, Kauczor HU, Wielpütz MO, Heussel CP. Prognostic Impact of CT-Quantified Muscle and Fat Distribution before and after First-Line-Chemotherapy in Lung Cancer Patients. *PLoS One* 2017; **12**: e0169136 [PMID: [28107410](#) DOI: [10.1371/journal.pone.0169136](#)]
- 24 **Shoji F**, Matsubara T, Kozuma Y, Haratake N, Akamine T, Takamori S, Katsura M, Toyokawa G, Okamoto T, Maehara Y. Relationship Between Preoperative Sarcopenia Status and Immuno-nutritional Parameters in Patients with Early-stage Non-small Cell Lung Cancer. *Anticancer Res* 2017; **37**: 6997-7003 [PMID: [29187486](#) DOI: [10.21873/anticancer.12168](#)]
- 25 **Abbass T**, Dolan RD, MacLeod N, Horgan PG, Laird BJ, McMillan DC. Comparison of the prognostic value of MUST, ECOG-PS, mGPS and CT derived body composition analysis in patients with advanced lung cancer. *Clin Nutr ESPEN* 2020; **40**: 349-356 [PMID: [33183562](#) DOI: [10.1016/j.clnesp.2020.08.003](#)]
- 26 **Dolan RD**, Maclay JD, Abbass T, Colville D, Buali F, MacLeod N, McSorley ST, Horgan PG, McMillan DC. The relationship between ¹⁸F-FDG-PETCT-derived tumour metabolic activity, nutritional risk, body composition, systemic inflammation and survival in patients with lung cancer. *Sci Rep* 2020; **10**: 20819 [PMID: [33257741](#) DOI: [10.1038/s41598-020-77269-7](#)]
- 27 **Magri V**, Gottfried T, Di Segni M, Urban D, Peled M, Daher S, Stoff R, Bar J, Onn A. Correlation of body composition by computerized tomography and metabolic parameters with survival of nivolumab-treated lung cancer patients. *Cancer Manag Res* 2019; **11**: 8201-8207 [PMID: [31564979](#) DOI: [10.2147/CMAR.S210958](#)]
- 28 **Roch B**, Coffy A, Jean-Baptiste S, Palaysi E, Daures JP, Pujol JL, Bommart S. Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors. *Lung Cancer* 2020; **143**: 19-26 [PMID: [32200137](#) DOI: [10.1016/j.lungcan.2020.03.003](#)]
- 29 **Katsui K**, Ogata T, Sugiyama S, Yoshio K, Kuroda M, Hiraki T, Kiura K, Maeda Y, Toyooka S, Kanazawa S. Sarcopenia is associated with poor prognosis after chemoradiotherapy in patients with stage III non-small-cell lung cancer: a retrospective analysis. *Sci Rep* 2021; **11**: 11882 [PMID: [34088965](#) DOI: [10.1038/s41598-021-91449-z](#)]
- 30 **Lee J**, Kim EY, Kim E, Kim KG, Kim YJ, Kim YS, Ahn HK, Lee SW. Longitudinal changes in skeletal muscle mass in patients with advanced squamous cell lung cancer. *Thorac Cancer* 2021; **12**: 1662-1667 [PMID: [33829665](#) DOI: [10.1111/1759-7714.13958](#)]
- 31 **Yang M**, Tan L, Xie L, Hu S, Liu D, Wang J, Li W. Factors That Improve Chest Computed Tomography-Defined Sarcopenia Prognosis in Advanced Non-Small Cell Lung Cancer. *Front Oncol* 2021; **11**: 754975 [PMID: [34660324](#) DOI: [10.3389/fonc.2021.754975](#)]
- 32 **Li D**, Yuan X, Liu J, Li C, Li W. Prognostic value of prognostic nutritional index in lung cancer: a meta-analysis. *J Thorac Dis* 2018; **10**: 5298-5307 [PMID: [30416777](#) DOI: [10.21037/jtd.2018.08.51](#)]
- 33 **Peng J**, Hao Y, Rao B, Cao Y. Prognostic impact of the pre-treatment controlling nutritional status score in patients with non-small cell lung cancer: A meta-analysis. *Medicine (Baltimore)* 2021; **100**: e26488 [PMID: [34190175](#) DOI: [10.1097/MD.00000000000026488](#)]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

